Benserazide

Benserazide is a peripheral decarboxylase inhibitor (PDI) that is often used in combination with levodopa for the treatment of Parkinson's disease. It was first synthesized in the 1960s by the Swiss pharmaceutical company Hoffmann-La Roche.

Etymology

The term "Benserazide" is derived from the chemical name N-benzylserine ethyl ester azide, which describes its chemical structure.

Pharmacology

Benserazide is a drug that is used to inhibit the metabolism of levodopa in the periphery, thus increasing the amount of levodopa that reaches the brain. It does this by inhibiting the enzyme dopa decarboxylase, which is responsible for the conversion of levodopa to dopamine in the body. By inhibiting this enzyme, benserazide allows more levodopa to reach the brain, where it can be converted to dopamine to treat the symptoms of Parkinson's disease.

Clinical Use

Benserazide is not used on its own as a drug, but is instead combined with levodopa in a fixed-dose combination to treat Parkinson's disease. This combination is known as co-beneldopa, and is available under various brand names including Madopar and Prolopa. The combination of levodopa and benserazide is designed to increase the effectiveness of levodopa treatment by ensuring that more of the drug reaches the brain.

Side Effects

Like all drugs, benserazide can cause side effects. These can include nausea, vomiting, abdominal pain, dyskinesia (involuntary movements), and psychiatric symptoms such as hallucinations and confusion. However, these side effects are generally less common and less severe than those caused by levodopa alone.

See Also

• Levodopa
• Parkinson's disease
• Dopa decarboxylase
• Co-beneldopa

Benserazide Resources
Latest articles Most recent articles Ongoing trials	Wikipedia